Use of probdnf regulator in b cell-related diseases
AssigneeShanghai Yile Biotechnology Limited
InventorsRuping DAI, Xiumei CAI, Huamao WANG
Life of this patent
Estimating the term…
Abstract
Disclosed is a use of a proBDNF regulator in B cell-related diseases. Specifically, disclosed is a use of a reagent which suppresses or activates proBDNF activity or proBDNF signaling pathways in preparing a regulator which regulates B lymphocyte function. Also disclosed is a use of a regulator in preparing a drug which treats B lymphocyte dysfunction-related diseases, a use of an antibody in preparing a reagent or reagent kit which detects/treats B lymphocyte dysfunction-related diseases, and a method for predicting a treatment or prevention effect of treating or preventing B lymphocyte dysfunction-related diseases.
Claims24
Use of an agent A method for inhibiting or activating the activity of proBDNF or proBDNF signaling pathway in preparing a regulator for regulating B lymphocyte function, wherein the proBDNF signaling pathway is selected from the group consisting of p75NTR signaling pathway, sortinlin signaling pathway, or SORCS2 signaling pathway.
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating a B lymphocyte dysfunction-related disease in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of a regulator selected from the group consisting of a proBDNF antagonist, p75NTR antagonist, Sortilin antagonist and SORCS2 antagonist.
(canceled)
A method for predicting the therapeutic or preventive effect of treating or preventing B lymphocyte dysfunction-related diseases, comprising the following steps:
- (1) detecting the expression level of proBDNF in a subject;
- (2) administering a regulator selected from the group consisting of a proBDNF antagonist, p75NTR antagonist, Sortilin antagonist and SORCS2 antagonist to the subject;
- (3) detecting the change in the expression level of proBDNF in the subject relative to (1) after the administration of the regulator shown in (2).
A kit for detecting/treating a B lymphocyte dysfunction-related disease in a subject comprising:
- (a) an antibody is selected from the group consisting of proBDNF antibody, p75NTR antibody, sortinlin antibody and SORCS2 antibody;
- and
- (b) instructions for use.
Dependencies are inferred from the claim text.